Vir Biotechnology, Inc. — Director's Dealing 2023

Apr 4, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vir Biotechnology, Inc. (VIR)
CIK: 0001706431
Period of Report: 2023-04-03

Reporting Person: De Backer Marianne (Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-04-03	Common Stock	A	576452	$0.00	Acquired	576452	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-04-03	Stock Option (Right to Buy)	$23.28	A	1152904	Acquired	2033-04-02	Common Stock (1152904)	Direct

Footnotes

F1: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.

F2: 25% of the shares subject to the stock option vest and become exercisable on April 3, 2024, and the remainder vest in 36 equal monthly installments thereafter.